TP53 and leukemia: We demonstrate that a p53 variant, which has partially lost the activity of wild-type p53 and by itself increases cancer susceptibility and promotes oncogene-driven development of leukemia and lymphoma, induces cancer regression in vivo when introduced into p53-deficient leukemia and lymphomas.